Excoriation Disorder Medication
- Author: Noah S Scheinfeld, JD, MD, FAAD; Chief Editor: Dirk M Elston, MD more...
Excoriation (skin-picking) disorder is treated with a variety of psychotropic medications. Medication classes that may be employed in this setting include antipsychotic agents, antianxiety agents, antidepressant agents, topical cortisone agents, and antiepileptic agents.
Adding venlafaxine to a treatment regimen of aripiprazole abated a case of treatment-resistant excoriation disorder.
Antipsychotic agents decrease the urge to scratch and relieve anxiety.
Doxepin inhibits histamine and acetylcholine activity and has proved useful in the treatment of various forms of depression associated with chronic and neuropathic pain.
Antianxiety agents are used to reduce the level of anxiety in patients who experience pruritus.
The mechanism of action of buspirone is unknown. It has high affinity for serotonin 5-HT1A and 5-HT2 receptors and moderate affinity for dopamine D2 receptors. It does not affect benzodiazepine-GABA receptors.
Antidepressants may be used to improve mood and to restore normal sleep patterns in patients who experience pruritus.
Fluoxetine selectively inhibits presynaptic serotonin reuptake, with minimal or no effect on reuptake of norepinephrine or dopamine.
Paroxetine (Paxil, Paxil CR, Pexeva)
Paroxetine is a potent selective inhibitor of neuronal serotonin reuptake. It has a weak effect on norepinephrine and dopamine neuronal reuptake. For maintenance therapy, make dosage adjustments to maintain the patient on the lowest effective dosage, and reassess the patient periodically to determine the need for continued treatment.
Fluvoxamine is a potent selective inhibitor of neuronal serotonin reuptake. It does not significantly bind to alpha-adrenergic, histamine, or cholinergic receptors and, thus, has fewer adverse effects than tricyclic antidepressants (TCAs).
Citalopram enhances serotonin activity by selective reuptake inhibition at the neuronal membrane. Although citalopram is not FDA approved for use in children, various clinical trials have shown efficacy in the treatment of moderate-to-severe major depressive disorder (MDD) in children and adolescents.
Escitalopram is the S-enantiomer of citalopram. It may have a faster onset of depression relief (1-2 wk) in comparison with other antidepressants.
Topical corticosteroids have anti-inflammatory properties and cause profound and varied metabolic effects. They modify the body’s immune response to diverse stimuli.
Topical triamcinolone treats inflammatory dermatosis that is responsive to steroids. It decreases inflammation by suppressing the migration of polymorphonuclear leukocytes and reversing capillary permeability.
Topical hydrocortisone is an adrenocorticosteroid derivative that is suitable for application to skin or external mucous membranes and is used to treat inflammatory dermatoses that are responsive to steroids. It decreases inflammation by suppressing the migration of polymorphonuclear leukocytes (PMNs) and reversing capillary permeability.
Topical betamethasone is used to treat inflammatory dermatoses responsive to steroids. It decreases inflammation by suppressing migration of PMNs and reversing capillary permeability. It affects production of lymphokines and has an inhibitory effect on Langerhans cells.
Clobetasol is a class I superpotent topical steroid. It suppresses mitosis and increases synthesis of proteins that decrease inflammation and cause vasoconstriction.
Antiepileptic agents decrease impulsiveness.
Topiramate is a sulfamate-substituted monosaccharide with a broad spectrum of antiepileptic activity that may have state-dependent sodium channel blocking action. It potentiates the inhibitory activity of gamma-aminobutyric acid (GABA) and may block glutamate activity.
Monitoring of plasma concentrations is not necessary for optimizing therapy. On occasion, addition of topiramate to phenytoin may necessitate adjustment of the phenytoin dosage to achieve optimal clinical outcome.
Jafferany M, Vander Stoep A, Dumitrescu A, Hornung RL. The knowledge, awareness, and practice patterns of dermatologists toward psychocutaneous disorders: results of a survey study. Int J Dermatol. 2010 Jul. 49(7):784-9. [Medline].
Brodin MB. Neurotic excoriations. J Am Acad Dermatol. 2010 Aug. 2:341-2. [Medline].
Leibovici V, Murad S, Cooper-Kazaz R, Tetro T, Keuthen NJ, Hadayer N, et al. Excoriation (skin picking) disorder in Israeli University students: prevalence and associated mental health correlates. Gen Hosp Psychiatry. 2014 Nov-Dec. 36(6):686-9. [Medline].
Snorrason I, Olafsson RP, Houghton DC, Woods DW, Lee HJ. 'Wanting' and 'liking' skin picking: A validation of the Skin Picking Reward Scale. J Behav Addict. 2015 Dec. 4(4):250-60. [Medline].
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, Va: American Psychiatric Association; 2013. 254-7.
Shah KN, Fried RG. Factitial dermatoses in children. Curr Opin Pediatr. 2006 Aug. 18(4):403-9. [Medline].
Gieler U, Consoli SG, Tomás-Aragones L, et al. Self-Inflicted Lesions in Dermatology: Terminology and Classification - A Position Paper from the European Society for Dermatology and Psychiatry (ESDaP). Acta Derm Venereol. 2013 Jan 10. 93(1):4-12. [Medline].
Koblenzer CS. Neurotic excoriations and dermatitis artefacta. Dermatol Clin. 1996 Jul. 14(3):447-55. [Medline].
Andreoli E, Finore ED, Provini A, Paradisi M. [Self-inflicted dermatitis: a case in pediatric age]. Minerva Pediatr. 2008 Jun. 60(3):355-9. [Medline].
Cyr PR, Dreher GK. Neurotic excoriations. Am Fam Physician. 2001 Dec 15. 64(12):1981-4. [Medline].
Anetakis Poulos G, Alghothani L, Bendo S, Zirwas MJ. Neurotic excoriations: a diagnosis of exclusion. J Clin Aesthet Dermatol. 2012 Feb. 5:3-4. [Medline].
Misery L, Chastaing M, Touboul S, et al. Psychogenic Skin Excoriations: Diagnostic Criteria, Semiological Analysis and Psychiatric Profiles. Acta Derm Venereol. 2012 Mar. [Medline].
Setyadi HG, Cohen PR, Schulze KE, et al. Trigeminal trophic syndrome. South Med J. 2007 Jan. 100(1):43-8. [Medline].
Odlaug BL, Hampshire A, Chamberlain SR, Grant JE. Abnormal brain activation in excoriation (skin-picking) disorder: evidence from an executive planning fMRI study. Br J Psychiatry. 2015 Jul 9. [Medline].
Paley K, Prevost N, English JC 3rd. Unna sleeve for neurotic excoriations. Cutis. 2010 Mar. 85(3):149-52. [Medline].
Krishnan A, Koo J. Psyche, opioids, and itch: therapeutic consequences. Dermatol Ther. 2005 Jul-Aug. 18(4):314-22. [Medline].
Grados MA, Atkins EB, Kovacikova GI, McVicar E. A selective review of glutamate pharmacological therapy in obsessive-compulsive and related disorders. Psychol Res Behav Manag. 2015 Apr 28. 8:115-31. [Medline].
Fellner MJ, Majeed MH. Tales of bugs, delusions of parasitosis, and what to do. Clin Dermatol. 2009 Jan-Feb. 27(1):135-8. [Medline].
Gupta MA, Gupta AK. Fluoxetine is an effective treatment for neurotic excoriations: case report. Cutis. 1993 May. 51(5):386-7. [Medline].
Gupta MA, Gupta AK. Olanzapine may be an effective adjunctive therapy in the management of acne excoriée: a case report. J Cutan Med Surg. 2001 Jan-Feb. 5(1):25-7. [Medline].
Biondi M, Arcangeli T, Petrucci RM. Paroxetine in a case of psychogenic pruritus and neurotic excoriations. Psychother Psychosom. 2000 May-Jun. 69(3):165-6. [Medline].
Gupta MA. Emotional regulation, dissociation, and the self-induced dermatoses: clinical features and implications for treatment with mood stabilizers. Clin Dermatol. 2013 Jan-Feb. 31(1):110-7. [Medline].
Dereli T, Karaca N, Inanir I, Oztürk G. Gabapentin for the treatment of recalcitrant chronic prurigo nodularis. Eur J Dermatol. 2008 Jan-Feb. 18(1):85-6. [Medline].
Shenefelt PD. Using hypnosis to facilitate resolution of psychogenic excoriations in acne excoriée. Am J Clin Hypn. 2004 Jan. 46(3):239-45. [Medline].
Fried RG. Nonpharmacologic treatments in psychodermatology. Dermatol Clin. 2002 Jan. 20(1):177-85. [Medline].
Turner GA, Sutton S, Sharma A. Augmentation of Venlafaxine with Aripiprazole in a Case of Treatment-resistant Excoriation Disorder. Innov Clin Neurosci. 2014 Jan. 11(1-2):29-31. [Medline].